Immunohistochemistry Leu 1 - CD15 Test, Price, Normal Range | Sprint Diagnostics Hyderabad

The IHC - Leu 1 (CD15) test helps determine the presence of Hodgkin's lymphoma and certain other cancers. The CD15 marker is expressed on Reed-Sternberg cells, characteristic of Hodgkin's lymphoma, and its identification can significantly aid in diagnosing and monitoring the disease.

No, fasting is not required for this test. The test uses tissue samples typically obtained through a biopsy procedure. Therefore, there are no dietary restrictions or specific preparations necessary before the test.

Your healthcare provider might order an IHC - Leu 1 (CD15) test if you show symptoms suggestive of Hodgkin's lymphoma or another cancer that often expresses the CD15 marker. The test is part of a broader diagnostic workup to confirm the disease presence and assess its extent.

The IHC - Leu 1 (CD15) test can identify the presence of CD15 in tissue samples. This information helps determine whether a patient has Hodgkin's lymphoma or another disease associated with CD15 expression. The test can also provide insight into the disease's severity and progression.

The frequency of the IHC - Leu 1 (CD15) test depends on the healthcare provider's recommendations, your symptoms, and the progression of any diagnosed conditions. The test may be repeated during treatment to monitor disease progression and response to therapy.

CD15 is typically expressed on certain types of white blood cells. Its presence in other tissue types or in increased amounts may suggest a pathological process, such as Hodgkin's lymphoma. However, the interpretation of results should always be performed by a qualified medical professional in the context of a patient's overall clinical picture.

No specific precautions are required for the IHC - Leu 1 (CD15) test. However, if a biopsy procedure is required to obtain a tissue sample, your healthcare provider will provide instructions to prepare for the procedure, including potential cessation of certain medications.

Various factors can impact the test results, including certain medications, health status, and technical aspects related to the tissue sample preparation and analysis.

If your test results are abnormal, you should consult the healthcare provider who ordered the test. This might be a hematologist, oncologist, or pathologist, depending on your symptoms and the reason the test was ordered.

The main risks associated with this test relate to the biopsy procedure used to obtain the tissue sample. These can include infection, bleeding, and discomfort at the site of the biopsy.

While the test alone cannot diagnose cancer, it can provide important information that aids in diagnosing certain types of cancer, especially Hodgkin's lymphoma, which frequently expresses the CD15 marker.

Yes, certain conditions, particularly those affecting the immune system or white blood cell count, can influence the results of the IHC - Leu 1 (CD15) test.

The detection of CD15 in your tissue sample could suggest a condition such as Hodgkin's lymphoma or another disease associated with CD15 expression. However, the results should be interpreted by a healthcare professional in the context of your overall clinical picture.

The IHC - Leu 1 (CD15) test can be performed during pregnancy if necessary. However, any biopsy procedures necessary to obtain a tissue sample should be discussed with your healthcare provider, considering the potential risks and benefits.

The IHC - Leu 1 (CD15) test involves treating a tissue sample with antibodies that specifically bind to CD15. These antibodies are linked to a dye or other visual marker, allowing any cells expressing CD15 to be identified under a microscope.

Modifiable factors affecting CD15 levels are few because its expression is primarily associated with certain types of cells and diseases. However, some treatments may impact its expression. Nonmodifiable factors include genetic predisposition and the presence of certain diseases, notably Hodgkin's lymphoma.

The presence or absence of CD15 can provide some information about the prognosis of Hodgkin's lymphoma and other conditions, but it's just one factor among many. Your healthcare provider will interpret the results in the context of other diagnostic information.

Depending on the results and your symptoms, your healthcare provider might recommend additional diagnostic tests, such as further immunohistochemical tests, molecular tests, or imaging studies, to get a better understanding of your condition.

The pain associated with the IHC - Leu 1 (CD15) test primarily comes from the biopsy procedure to collect the tissue sample. You may experience a prick or pressure sensation during the procedure, but pain relief measures can be taken.

After the test, your healthcare provider will review the results with you. If CD15 is detected, it could indicate the presence of Hodgkin's lymphoma or another condition, and further investigations or treatment may be necessary.